Elfabrio (pegunigalsidase alfa)
Fabry disease · Metabolic (Fabry)
About Elfabrio
Elfabrio (pegunigalsidase alfa) is a enzyme replacement manufactured by Chiesi/Protalix, used in the treatment of Fabry disease. It received FDA approval in 2023 under the Traditional pathway.
Accessing Elfabrio through Reserve Meds
We help patients in the Middle East, India, Africa, and other regions access Elfabrio via established Named Patient Program (NPP) and personal-import pathways. Every order requires a prescription from a licensed physician in the destination country.
What we need from you
- A prescription from a licensed physician in your country of residence.
- A clinical justification from the prescribing physician (why Elfabrio for this patient).
- Destination-country NPP or personal-import paperwork (we help prepare these).
- Patient consent for cross-border drug import under the applicable pathway.
Typical timeline
From request to delivery, most orders for Elfabrio are completed in 2-6 weeks. Timing varies by destination country regulatory review speed and physician documentation turnaround.
Indication context
Elfabrio is indicated for Fabry disease. The condition falls within Metabolic (Fabry). For patients with this condition in countries where Elfabrio is not yet registered, NPP access is typically the primary legal pathway for obtaining treatment.
About the manufacturer
Elfabrio is manufactured by Chiesi/Protalix. We source drug supply exclusively through DSCSA-compliant US specialty wholesalers, ensuring every unit is authentic, serialized, and chain-of-custody documented.
International regulatory status
- United States: FDA approved (2023).
- EMA (EU): Approved.
- MHRA (UK): Approved.
- Other countries: Approval status varies. Reserve Meds coordinates access under each destination country's NPP pathway.
Start a request for Elfabrio
If you or a family member needs Elfabrio and it is not available in your country, submit a request. Our clinical team will review eligibility and respond within one business day.
Elfabrio — country access pages
Information on how patients in different countries access Elfabrio through Named Patient Program pathways.
- Elfabrio in United Arab Emirates — The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.
- Elfabrio in Saudi Arabia — The Saudi Food and Drug Authority (SFDA) operates a Personal Import / Unregistered Medicine pathway for named patients, typically requiring physician justification and hospital ethics-committee review.
- Elfabrio in India — India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.
- Elfabrio in Kuwait — Kuwait's Ministry of Health operates a Personal Import pathway for specialty drugs not registered locally, typically through a hospital pharmacy with physician attestation.
- Elfabrio in Qatar — Qatar's MoPH permits unregistered drug import under a named-patient pathway with physician and MoPH approval; Hamad Medical Corp frequently sponsors.
- Elfabrio in Bahrain — Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Pharmacist (see Trust & Compliance).